Drugs / ApoGraft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04006652 | Dec 2020 → Dec 2022 | acute graft versus host disease | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ApoGraft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04006652 ↗ |
| Action | Deplete | “Fas receptor mediated selective depletion of T cell subsets, ex vivo.” NCT04006652 ↗ |
| Modality | Cell therapy | “ApoGraft is a cell based product, manufactured with mobilized peripheral blood.” NCT04006652 ↗ |
| Route | Other | “Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines” NCT04006652 ↗ |